COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02204644
Recruitment Status : Completed
First Posted : July 30, 2014
Last Update Posted : February 27, 2018
Information provided by (Responsible Party):
Jiangsu Hansoh Pharmaceutical Co., Ltd.